Kimberly Dobbs, MD
Pulmonary Disease · Jackson, MSNPI 1265456818
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 71.8% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $10,379, more than ten times the $76 reported in 2019.
Across 186 payments — averaging $72.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- Olympus Corporation Of The Americas$858
- GSK$385
- Mallinckrodt Hospital Products Inc.$339
- Pfizer$300
- Actelion Pharmaceuticals US, Inc.$294
- plus $2K from 18 others
Across 6 payments — averaging $3521.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$21K
What the payments were for
- Consulting fees$6,07545%
- Travel & lodging$3,55426%
- Food & beverage$3,93429%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 38 | $9,746 |
| Olympus Corporation Of The Americas | 8 | $858 |
| GSK | 18 | $385 |
| Mallinckrodt Hospital Products Inc. | 14 | $339 |
| Pfizer | 15 | $300 |
| Actelion Pharmaceuticals US, Inc. | 12 | $294 |
| Sanofi | 6 | $231 |
| Merck | 12 | $225 |
| Bayer | 9 | $151 |
| AstraZeneca | 9 | $146 |
| Grifols USA, LLC | 8 | $143 |
| ANI Pharmaceuticals, Inc. | 4 | $121 |
| Inari Medical, Inc. | 4 | $93 |
| Pulmonx Corporation | 4 | $72 |
| Ambu Inc. | 2 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Insmed, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| United Therapeutics Corporation | 4 | $51 |
| La Jolla Pharmaceutical Company | 2 | $49 |
| Verona Pharma, Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 4 | $29 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,674
- SINGLE USE SUCTION VALVE (Sterile)$698
- DUPIXENT$209
How this compares
$13,565 in reported general payments places this provider in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 51 | $636,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $81,885 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $27,599 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,323 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $11,892 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,174 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $4,480 |
| Roflumilast | 15 | $3,448 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $3,016 |
| Mycophenolate Mofetil | 29 | $1,468 |
| Ventolin HfaAlbuterol Sulfate | 15 | $816 |
| Prednisone | 112 | $524 |
| Azithromycin | 26 | $336 |
| Fluticasone Propionate | 20 | $306 |
| MethotrexateMethotrexate Sodium | 25 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $9,746 | $646,53565 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $385 | $126,807195 claims |
| AstraZenecaSymbicort | $146 | $11,89249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.